The global sartans market is expected to grow from USD 2.2 billion in 2016 to USD 3.5 billion by 2030, at a CAGR of 5.1% during the forecast period. The market is segmented on the basis of type, application, and region. In terms of type, valsartan segment accounts for the largest share among all types due to its large therapeutic scope covering various indications such as hypertension and cardiovascular diseases. Telmisartan has registered highest CAGR during forecast period due to increased use in treatment of cardiovascular diseases with an increase in awareness about renal protection offered by this drug among physicians and patients across the globe.
Global Sartans Market By Type (Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan), By Application (Hypertension And Cardiovascular Diseases) And By Region - Forecast From 2021 To 2030.
Hypertension is a major contributor to global population health burden accounting up to 31% of all deaths worldwide. The majority of people are aware that high blood pressure can lead to stroke or heart attack which can lead them into death but they do not know that it also causes problem such as kidney failure, sleep apnea, damage in arteries and eyes etc Renal protection offered by telmisartan allows patients with hypertension to avoid these side effects like kidney disease which ultimately reduces mortality rates globally.
By application type, hypertension and cardiovascular diseases account for the largest share due to their higher prevalence rate as compared with other indications such as diabetes mellitus type 2 and risk factors for coronary artery disease. Rise in prevalence rates (due increase in population) coupled with increased awareness about benefits associated will drive demand over next decade.
Industry Growth Insights published a new data on “Sartans Market”. The research report is titled “Sartans Market research by Types (Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan), By Applications (Hypertension, Cardiovascular Diseases, Kidney Diseases, Other), By Players/Companies Pfizer, Novartis, Merck, Astra Zeneca, Jhonson and Johnson, Eli Lilly, Sanofi, Bristol-Myers Squibb, Bayer, GSK, Teva Pharmaceutical”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Sartans Market Research Report
By Type
Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan
By Application
Hypertension, Cardiovascular Diseases, Kidney Diseases, Other
By Companies
Pfizer, Novartis, Merck, Astra Zeneca, Jhonson and Johnson, Eli Lilly, Sanofi, Bristol-Myers Squibb, Bayer, GSK, Teva Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
237
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Sartans Market Report Segments:
The global Sartans market is segmented on the basis of:
Types
Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hypertension, Cardiovascular Diseases, Kidney Diseases, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Novartis
- Merck
- Astra Zeneca
- Jhonson and Johnson
- Eli Lilly
- Sanofi
- Bristol-Myers Squibb
- Bayer
- GSK
- Teva Pharmaceutical
Highlights of The Sartans Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Valsartan
- Telmisartan
- Losartan
- Irbesartan
- Azilsartan
- Olmesartan
- By Application:
- Hypertension
- Cardiovascular Diseases
- Kidney Diseases
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Sartans Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Sartans is a brand of clothing and accessories.
Some of the major companies in the sartans market are Pfizer, Novartis, Merck, Astra Zeneca, Jhonson and Johnson, Eli Lilly, Sanofi, Bristol-Myers Squibb, Bayer, GSK, Teva Pharmaceutical.
The sartans market is expected to grow at a compound annual growth rate of 5.1%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Sartans Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Sartans Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Sartans Market - Supply Chain
4.5. Global Sartans Market Forecast
4.5.1. Sartans Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Sartans Market Size (000 Units) and Y-o-Y Growth
4.5.3. Sartans Market Absolute $ Opportunity
5. Global Sartans Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Sartans Market Size and Volume Forecast by Type
5.3.1. Valsartan
5.3.2. Telmisartan
5.3.3. Losartan
5.3.4. Irbesartan
5.3.5. Azilsartan
5.3.6. Olmesartan
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Sartans Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Sartans Market Size and Volume Forecast by Application
6.3.1. Hypertension
6.3.2. Cardiovascular Diseases
6.3.3. Kidney Diseases
6.3.4. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Sartans Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Sartans Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Sartans Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Sartans Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Sartans Demand Share Forecast, 2019-2026
9. North America Sartans Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Sartans Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Sartans Market Size and Volume Forecast by Application
9.4.1. Hypertension
9.4.2. Cardiovascular Diseases
9.4.3. Kidney Diseases
9.4.4. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Sartans Market Size and Volume Forecast by Type
9.7.1. Valsartan
9.7.2. Telmisartan
9.7.3. Losartan
9.7.4. Irbesartan
9.7.5. Azilsartan
9.7.6. Olmesartan
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Sartans Demand Share Forecast, 2019-2026
10. Latin America Sartans Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Sartans Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Sartans Market Size and Volume Forecast by Application
10.4.1. Hypertension
10.4.2. Cardiovascular Diseases
10.4.3. Kidney Diseases
10.4.4. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Sartans Market Size and Volume Forecast by Type
10.7.1. Valsartan
10.7.2. Telmisartan
10.7.3. Losartan
10.7.4. Irbesartan
10.7.5. Azilsartan
10.7.6. Olmesartan
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Sartans Demand Share Forecast, 2019-2026
11. Europe Sartans Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Sartans Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Sartans Market Size and Volume Forecast by Application
11.4.1. Hypertension
11.4.2. Cardiovascular Diseases
11.4.3. Kidney Diseases
11.4.4. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Sartans Market Size and Volume Forecast by Type
11.7.1. Valsartan
11.7.2. Telmisartan
11.7.3. Losartan
11.7.4. Irbesartan
11.7.5. Azilsartan
11.7.6. Olmesartan
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Sartans Demand Share, 2019-2026
12. Asia Pacific Sartans Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Sartans Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Sartans Market Size and Volume Forecast by Application
12.4.1. Hypertension
12.4.2. Cardiovascular Diseases
12.4.3. Kidney Diseases
12.4.4. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Sartans Market Size and Volume Forecast by Type
12.7.1. Valsartan
12.7.2. Telmisartan
12.7.3. Losartan
12.7.4. Irbesartan
12.7.5. Azilsartan
12.7.6. Olmesartan
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Sartans Demand Share, 2019-2026
13. Middle East & Africa Sartans Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Sartans Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Sartans Market Size and Volume Forecast by Application
13.4.1. Hypertension
13.4.2. Cardiovascular Diseases
13.4.3. Kidney Diseases
13.4.4. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Sartans Market Size and Volume Forecast by Type
13.7.1. Valsartan
13.7.2. Telmisartan
13.7.3. Losartan
13.7.4. Irbesartan
13.7.5. Azilsartan
13.7.6. Olmesartan
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Sartans Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Sartans Market: Market Share Analysis
14.2. Sartans Distributors and Customers
14.3. Sartans Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Pfizer
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Novartis
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Merck
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Astra Zeneca
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Jhonson and Johnson
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Eli Lilly
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Sanofi
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Bristol-Myers Squibb
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Bayer
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. GSK
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Teva Pharmaceutical
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
